A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
Conditions
Solid Tumours Harboring NRG1 Fusion · NSCLC Harboring NRG1 Fusion · Pancreatic Cancer Harboring NRG1 Fusion · NRG1 Fusion
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Mayo Clinic, Phoenix, Arizona, United States
The Oncology Institute of Hope and Innovation, Cerritos, California, United States
University of California Irvine, Irvine, California, United States
Stanford University, Palo Alto, California, United States
Sharp Memorial Hospital, San Diego, California, United States
Georgetown University, Washington D.C., District of Columbia, United States
Memorial Cancer Institute, Hollywood, Florida, United States
Cancer Specialists of North Florida, Jacksonville, Florida, United States
Mayo Clinic, Jacksonville, Florida, United States
Emory Winship Cancer Institute, Atlanta, Georgia, United States
Northwest Oncology & Hematology, Rolling Meadows, Illinois, United States
Dana Farber Cancer Center, Boston, Massachusetts, United States
Karmanos Cancer Center, Detroit, Michigan, United States
Mayo Clinic, Rochester, Minnesota, United States
Billings Clinic Cancer Center, Billings, Montana, United States
St. James Healthcare, Butte, Montana, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Averra Medical Group, Sioux Falls, South Dakota, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Utah Cancer Specialists, Salt Lake City, Utah, United States
Hematology-Oncology Specialist of Fredericksburg, Fredericksburg, Virginia, United States
Virginia Mason Hospital & Seattle Medical Center, Seattle, Washington, United States
Hematology Oncology Associates, Spokane, Washington, United States
Northwest Medical Specialties, Tacoma, Washington, United States
Salzburger Universitatsklinikum, Salzburg, Austria
UZ Leuven, Leuven, Belgium
Princess MargaretCancer Centre, Toronto, Ontario, Canada
Rigshospitalet, Copenhagen, Denmark
Centre Leon Berard, Lyon, France
Hospital Louis Pradel, FR, Lyon, France
Institut Gustave Roussy, Paris, France
Hopital Cochin, Paris, France
Hopital Curie, Paris, France
Asklepios Klinik Altona, Hamburg, Germany
Asklepios Kliniken Hamburg GmbH, Hamburg, Germany
Deutsches Krebsforschungszentrum, Heidelberg, Germany
Shaare Zedek Medical Center, Jerusalem, Israel
Sheba Medical Center, Tel Aviv, Israel
Niguarda Cancer Centre, Milan, Italy
Ospedale San Raffaele, Milan, Italy
Istituti Fisioterapici Ospitalieri, Roma, Italy
National Cancer Center Hospital, Chūōku, Japan
St. Marianna University School of Medicine Hospital, Kawasaki, Japan
Osaka International Cancer Institute, Osaka, Japan
National Cancer Center East, Tokyo, Japan
NKI, Amsterdam, Netherlands
Amsterdam Medical Center, Amsterdam, Netherlands
Radboud University Medical Center, Nijmegen, Netherlands
University Hospital Oslo, Oslo, Norway
National Cancer Centre of Singapore PTE LTD, Singapore, Singapore, Singapore
Samsung Medical Center, Seoul, South Korea
Seoul National University College of Medicine, Seoul, South Korea
Severance Hospital- Yonsei Cancer Center, Seoul, South Korea
Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain
START Hospital Fundación Jiménez Diaz, Madrid, Spain
START Hospital Universitario Madrid Sanchinarro, Madrid, Spain
Hospital 12 de Octubre, Madrid, Spain
Clínica Universidad de Navarra, Pamplona, Spain
Instituto Valenciano Oncologia, Valencia, Spain
Karolinska Universitetssjukhuset, Solna, Sweden
National Taiwan University Hospital 7, Taipei, Taiwan
Sarah Cannon Research Institute, London, United Kingdom
Study leads
Alison Schram, MD
Principal Investigator
Memorial Sloan Kettering Medical Center